Tomivosertib

DRUG3 trials

Sponsors

Translational Research in Oncology, Effector Therapeutics, Northwestern University

Conditions

Acute Myeloid LeukemiaBreast CancerNon-small Cell Lung Cancer

Phase 1

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

CompletedNCT04261218

Translational Research in OncologyBreast Cancer

Start: 2020-08-25End: 2022-07-04Updated: 2022-07-20

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

TerminatedNCT05744739

Northwestern UniversityAcute Myeloid Leukemia

Start: 2023-09-29End: 2024-08-20Updated: 2026-06-11

Phase 2

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Active, not recruitingNCT04622007

Effector TherapeuticsNon-small Cell Lung Cancer

Start: 2021-06-02End: 2024-12-09Updated: 2024-04-30

Related Papers

Abstract CT521: Phase 1b trial of the MNK1/2 inhibitor tomivosertib combined with paclitaxel in patients with metastatic breast cancer

Cancer Research2022-06-15